Mia Jose
Research Subjects
Mia Jose has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Annabelle Santos Volgman
Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA
1 shared publication - Devika Adusumilli
Department of Internal Medicine, Medical City Hospital , Fort Worth, TX
1 shared publication - Estelle Torbey
Division of Cardiology, Brown University Medical Center, Providence, RI 02914, USA
1 shared publication - Ian Curnutt
Department of Internal Medicine, Kansas City University College of Osteopathic Medicine, Joplin, MO 64804, USA
1 shared publication - Jorge A. Irizarry-Caro
Division of Cardiology, UT San Antonio, San Antonio, TX 77030, USA
1 shared publication - Kamala P. Tamirisa
Department of Cardiovascular Medicine, University of Texas Southwestern Medical Center , Dallas, TX
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (7) , 343
Arrhythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management
Autoimmune diseases substantially increase the risk of atrial and ventricular arrhythmias and sudden cardiac death through shared immune-mediated mechanisms. Pro-inflammatory cytokines, autoantibodies, and progressive myocardial fibrosis disrupt ion channel function, impair conduction, and create re-entrant substrates. Across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), these pathways manifest as atrial fibrillation, ventricular arrhythmias, conduction disease, and heightened arrhythmic mortality. Anti Ro/SSA antibodies, in particular, contribute to QT prolongation and atrioventricular (AV) block, while cytokines such as TNF α, IL 1β, and IL 6 remodel electrophysiological properties and promote fibrosis. Advanced cardiac imaging, especially cardiac magnetic resonance (CMR), detects inflammation and fibrosis even when ejection fraction is preserved, enabling earlier intervention. Management requires a dual approach: standard arrhythmia therapies alongside aggressive control of systemic inflammation with disease-specific immunosuppression. Despite growing evidence, major gaps remain, including the absence of randomized trials targeting immune-driven arrhythmias and the need for integrated risk models incorporating inflammatory biomarkers.
- 22 July 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (7) , 343
Open AccessArrhythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management
Autoimmune diseases substantially increase the risk of atrial and ventricular arrhythmias and sudden cardiac death through shared immune-mediated mechanisms. Pro-inflammatory cytokines, autoantibodies, and progressive myocardial fibrosis disrupt ion channel function, impair conduction, and create re-entrant substrates. Across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), these pathways manifest as atrial fibrillation, ventricular arrhythmias, conduction disease, and heightened arrhythmic mortality. Anti Ro/SSA antibodies, in particular, contribute to QT prolongation and atrioventricular (AV) block, while cytokines such as TNF α, IL 1β, and IL 6 remodel electrophysiological properties and promote fibrosis. Advanced cardiac imaging, especially cardiac magnetic resonance (CMR), detects inflammation and fibrosis even when ejection fraction is preserved, enabling earlier intervention. Management requires a dual approach: standard arrhythmia therapies alongside aggressive control of systemic inflammation with disease-specific immunosuppression. Despite growing evidence, major gaps remain, including the absence of randomized trials targeting immune-driven arrhythmias and the need for integrated risk models incorporating inflammatory biomarkers.